Infant mortality and adult stature in Spain.

C. Quintana‐Domeque,C. Bozzoli,Mariano Bosch

DOI: https://doi.org/10.1016/j.socscimed.2011.03.042

2011-06-01

Social Science & Medicine (1967)

Abstract:

What problem does this paper attempt to address?

Computer Simulation of Vitamin D Transport

J. Dunn

DOI: https://doi.org/10.1111/j.1749-6632.1988.tb48851.x

IF: 6.499

1988-09-01

Annals of the New York Academy of Sciences

Abstract:In man, vitamin D and its metabolites circulate in complex with plasma proteins including vitamin D-binding protein (DBP, also known as group specific component or Gc protein) and albumin.'-* The major portion is bound with high affinity to DBP and relatively low affinity to serum albumin. Most investigators agree that the binding of hormones to transport proteins affects their entry and subsequent biological activity at various target tissues, and that determination of the plasma distribution of these hormones may provide important information concerning their metabolism and biological activity in vivo. Accordingly, we have used a computer model to characterize the in vivo plasma distribution of vitamin D and its metabolites with particular attention to 1,25-dihydroxyvitamin D.
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee

Sharon L. Kolasinski,Tuhina Neogi,Marc C. Hochberg,Carol Oatis,Gordon Guyatt,Joel Block,Leigh Callahan,Cindy Copenhaver,Carole Dodge,David Felson,Kathleen Gellar,William F. Harvey,Gillian Hawker,Edward Herzig,C. Kent Kwoh,Amanda E. Nelson,Jonathan Samuels,Carla Scanzello,Daniel White,Barton Wise,Roy D. Altman,Dana DiRenzo,Joann Fontanarosa,Gina Giradi,Mariko Ishimori,Devyani Misra,Amit Aakash Shah,Anna K. Shmagel,Louise M. Thoma,Marat Turgunbaev,Amy S. Turner,James Reston

DOI: https://doi.org/10.1002/art.41142

2020-01-06

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>To develop an evidence‐based guideline for the comprehensive management of osteoarthritis (OA) as a collaboration between the American College of Rheumatology (ACR) and the Arthritis Foundation, updating the 2012 ACR recommendations for the management of hand, hip, and knee OA.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>We identified clinically relevant population, intervention, comparator, outcomes questions and critical outcomes in OA. A Literature Review Team performed a systematic literature review to summarize evidence supporting the benefits and harms of available educational, behavioral, psychosocial, physical, mind‐body, and pharmacologic therapies for OA. Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of the evidence. A Voting Panel, including rheumatologists, an internist, physical and occupational therapists, and patients, achieved consensus on the recommendations.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Based on the available evidence, either strong or conditional recommendations were made for or against the approaches evaluated. Strong recommendations were made for exercise, weight loss in patients with knee and/or hip OA who are overweight or obese, self‐efficacy and self‐management programs, tai chi, cane use, hand orthoses for first carpometacarpal (CMC) joint OA, tibiofemoral bracing for tibiofemoral knee OA, topical nonsteroidal antiinflammatory drugs (NSAIDs) for knee OA, oral NSAIDs, and intraarticular glucocorticoid injections for knee OA. Conditional recommendations were made for balance exercises, yoga, cognitive behavioral therapy, kinesiotaping for first CMC OA, orthoses for hand joints other than the first CMC joint, patellofemoral bracing for patellofemoral knee OA, acupuncture, thermal modalities, radiofrequency ablation for knee OA, topical NSAIDs, intraarticular steroid injections and chondroitin sulfate for hand OA, topical capsaicin for knee OA, acetaminophen, duloxetine, and tramadol.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>This guideline provides direction for clinicians and patients making treatment decisions for the management of OA. Clinicians and patients should engage in shared decision‐making that accounts for patients' values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.</p></section>

rheumatology
Tyrosine Phosphorylation of the Gα-Interacting Protein GIV Promotes Activation of Phosphoinositide 3-Kinase During Cell Migration

Changsheng Lin,Jason Ear,Yelena Pavlova,Y. Mittal,I. Kufareva,M. Ghassemian,R. Abagyan,M. Garcia-Marcos,P. Ghosh

DOI: https://doi.org/10.1126/scisignal.2002049

IF: 9.517

2011-09-27

Science Signaling

Abstract:GIV links ligand stimulation of various receptors to downstream activation of a kinase involved in cell migration. GIVing Migration a Boost Phosphoinositide 3-kinase (PI3K) can promote cell migration, and the activation of PI3K occurs downstream of ligand binding to several cell surface receptors. Lin et al. show that the guanine nucleotide exchange factor GIV (Gα-interacting vesicle-associated protein) may link ligand stimulation of these receptors to activation of PI3K. GIV was tyrosine phosphorylated by various receptor and non-receptor tyrosine kinases, and these phosphorylation events enabled GIV to bind to a regulatory subunit of PI3K, increase PI3K activity at the plasma membrane, and promote cell migration. The metastatic and invasive extent of a breast carcinoma was positively correlated to tyrosine phosphorylation of GIV and its association with the regulatory subunit of PI3K. Thus, manipulations that prevent or decrease the tyrosine phosphorylation of GIV could potentially be used to slow the progression of invasive cancers. GIV (Gα-interacting vesicle-associated protein; also known as Girdin) enhances Akt activation downstream of multiple growth factor– and G protein (heterotrimeric guanosine 5′-triphosphate–binding protein)–coupled receptors to trigger cell migration and cancer invasion. We demonstrate that GIV is a tyrosine phosphoprotein that directly binds to and activates phosphoinositide 3-kinase (PI3K). Upon ligand stimulation of various receptors, GIV was phosphorylated at tyrosine-1764 and tyrosine-1798 by both receptor and non-receptor tyrosine kinases. These phosphorylation events enabled direct binding of GIV to the amino- and carboxyl-terminal Src homology 2 domains of p85α, a regulatory subunit of PI3K; stabilized receptor association with PI3K; and enhanced PI3K activity at the plasma membrane to trigger cell migration. Tyrosine phosphorylation of GIV and its association with p85α increased during metastatic progression of a breast carcinoma. These results suggest a mechanism by which multiple receptors activate PI3K through tyrosine phosphorylation of GIV, thereby making the GIV-PI3K interaction a potential therapeutic target within the PI3K-Akt pathway.
American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee

Marc C. Hochberg,Roy D. Altman,Karine Toupin April,Maria Benkhalti,Gordon Guyatt,Jessie McGowan,Tanveer Towheed,Vivian Welch,George Wells,Peter Tugwell

DOI: https://doi.org/10.1002/acr.21596

2012-03-27

Abstract:OBJECTIVE: To update the American College of Rheumatology (ACR) 2000 recommendations for hip and knee osteoarthritis (OA) and develop new recommendations for hand OA.METHODS: A list of pharmacologic and nonpharmacologic modalities commonly used to manage knee, hip, and hand OA as well as clinical scenarios representing patients with symptomatic hand, hip, and knee OA were generated. Systematic evidence-based literature reviews were conducted by a working group at the Institute of Population Health, University of Ottawa, and updated by ACR staff to include additions to bibliographic databases through December 31, 2010. The Grading of Recommendations Assessment, Development and Evaluation approach, a formal process to rate scientific evidence and to develop recommendations that are as evidence based as possible, was used by a Technical Expert Panel comprised of various stakeholders to formulate the recommendations for the use of nonpharmacologic and pharmacologic modalities for OA of the hand, hip, and knee.RESULTS: Both “strong” and “conditional” recommendations were made for OA management. Modalities conditionally recommended for the management of hand OA include instruction in joint protection techniques, provision of assistive devices, use of thermal modalities and trapeziometacarpal joint splints, and use of oral and topical nonsteroidal antiinflammatory drugs (NSAIDs), tramadol, and topical capsaicin. Nonpharmacologic modalities strongly recommended for the management of knee OA were aerobic, aquatic, and/or resistance exercises as well as weight loss for overweight patients. Nonpharmacologic modalities conditionally recommended for knee OA included medial wedge insoles for valgus knee OA, subtalar strapped lateral insoles for varus knee OA, medially directed patellar taping, manual therapy, walking aids, thermal agents, tai chi, self management programs, and psychosocial interventions. Pharmacologic modalities conditionally recommended for the initial management of patients with knee OA included acetaminophen, oral and topical NSAIDs, tramadol, and intraarticular corticosteroid injections; intraarticular hyaluronate injections, duloxetine, and opioids were conditionally recommended in patients who had an inadequate response to initial therapy. Opioid analgesics were strongly recommended in patients who were either not willing to undergo or had contraindications for total joint arthroplasty after having failed medical therapy. Recommendations for hip OA were similar to those for the management of knee OA.CONCLUSION: These recommendations are based on the consensus judgment of clinical experts from a wide range of disciplines, informed by available evidence, balancing the benefits and harms of both nonpharmacologic and pharmacologic modalities, and incorporating their preferences and values. It is hoped that these recommendations will be utilized by health care providers involved in the management of patients with OA.

rheumatology
Surgical management of osteoarthritis of the knee: evidence-based clinical practice guideline methodological interpretation and recommendations explanation

Dan XING,Yaolong CHEN,Qi WANG,Xiaoqin WANG,Liang DU,Jianhao LIN

DOI: https://doi.org/10.7507/1672-2531.201802043

2018-01-01

Abstract:Surgical management of osteoarthritis of the knee: evidence based guideline contains 38 recommendations pertaining to the preoperative, perioperative, and postoperative care of patients with knee osteoarthritis (KOA) who are considering surgical treatment. Compared with the domestic consensus on diagnosis and treatment for KOA, this clinical practice guideline (CPG) prepared by the American Academy of Orthopedic Surgeons (AAOS) has some advantages in terms of methodology selection and recommendation. Therefore, it is necessary for us to interpret this CPG to speed up the understanding and dissemination of the CPG. The ultimate aims are to: ① strengthen the standardization and understanding of surgical treatment of KOA; ② enhance the understanding of clinicians for this CPG in treating KOA; ③ speed up the development of guideline development methodologies in China; ④ provide methodological guidance for the development of CPG based on the current situation in China.
Nonarthritic hip joint pain

Keelan Enseki,Marcie Harris-Hayes,Douglas M White,Michael T Cibulka,Judith Woehrle,Timothy L Fagerson,John C Clohisy,Orthopaedic Section of the American Physical Therapy Association

DOI: https://doi.org/10.2519/jospt.2014.0302

Abstract:The Orthopaedic Section of the American Physical Therapy Association (APTA) has an ongoing effort to create evidence-based practice guidelines for orthopaedic physical therapy management of patients with musculoskeletal impairments described in the World Health Organization's International Classification of Functioning, Disability, and Health (ICF). The purpose of these clinical practice guidelines is to describe the peer-reviewed literature and make recommendations related to nonarthritic hip joint pain.
Management of hip fractures in the elderly.

W. T. Brox,Kaitlyn S. Sevarino,K. Roberts,D. Jevsevar

DOI: https://doi.org/10.5435/JAAOS-D-14-00432

IF: 4

2015-02-01

Journal of the American Academy of Orthopaedic Surgeons

Abstract:The purpose of this clinical practice guideline is to help improve treatment and management of hip fractures in the elderly based on current best evidence. The guideline contains twenty-five recommendations, including both diagnosis and treatment. Of those recommendations, strong evidence supports regional analgesia to improve preoperative pain control, similar outcomes for general or spinal anesthesia, arthroplasty for patients with unstable (displaced) femoral neck fractures, the use of a cephalomedullary device for the treatment of patients with subtrochanteric or reverse obliquity fractures, a blood transfusion threshold of no higher than 8 g/dL in asymptomatic postoperative patients, intensive physical therapy postdischarge, use of an interdisciplinary care program in patients with mild to moderate dementia, and multimodal pain management after hip fracture surgery. In addition to the recommendations, the work group highlighted the need for better research in the treatment of hip fractures.

Medicine
A critical appraisal of guidelines for the management of knee osteoarthritis using Appraisal of Guidelines Research and Evaluation criteria

Stéphane Poitras,Jérôme Avouac,Michel Rossignol,Bernard Avouac,Christine Cedraschi,Margareta Nordin,Chantal Rousseaux,Sylvie Rozenberg,Bernard Savarieau,Philippe Thoumie,Jean-Pierre Valat,Éric Vignon,Pascal Hilliquin

DOI: https://doi.org/10.1186/ar2339

2007-01-01

Abstract:Clinical practice guidelines have been elaborated to summarize evidence related to the management of knee osteoarthritis and to facilitate uptake of evidence-based knowledge by clinicians. The objectives of the present review were summarizing the recommendations of existing guidelines on knee osteoarthritis, and assessing the quality of the guidelines using a standardized and validated instrument – the Appraisal of Guidelines Research and Evaluation (AGREE) tool. Internet medical literature databases from 2001 to 2006 were searched for guidelines, with six guidelines being identified. Thirteen clinician researchers participated in the review. Each reviewer was trained in the AGREE instrument. The guidelines were distributed to four groups of three or four reviewers, each group reviewing one guideline with the exception of one group that reviewed two guidelines. One independent evaluator reviewed all guidelines. All guidelines effectively addressed only a minority of AGREE domains. Clarity/presentation was effectively addressed in three out of six guidelines, scope/purpose and rigour of development in two guidelines, editorial independence in one guideline, and stakeholder involvement and applicability in none. The clinical management recommendation tended to be similar among guidelines, although interventions addressed varied. Acetaminophen was recommended for initial pain treatment, combined with exercise and education. Nonsteroidal anti-inflammatory drugs were recommended if acetaminophen failed to control pain, but cautiously because of gastrointestinal risks. Surgery was recommended in the presence of persistent pain and disability. Education and activity management interventions were superficially addressed in most guidelines. Guideline creators should use the AGREE criteria when developing guidelines. Innovative and effective methods of knowledge translation to health professionals are needed.

rheumatology
A Systematic Review of Current Clinical Practice Guidelines on Intra-articular Hyaluronic Acid, Corticosteroid, and Platelet-Rich Plasma Injection for Knee Osteoarthritis: An International Perspective

Mark Phillips,Mohit Bhandari,John Grant,Asheesh Bedi,Thomas Trojian,Aaron Johnson,Emil Schemitsch

DOI: https://doi.org/10.1177/23259671211030272

IF: 2.6

2021-08-01

Orthopaedic Journal of Sports Medicine

Abstract:Background: There are many clinical practice guidelines (CPGs) for the prevention, diagnosis, and treatment of knee osteoarthritis (OA). They differ by region, considering local health care systems, along with cultural and economic factors. Currently, there are conflicting CPG recommendations across the various publications, which makes it difficult for clinicians to fully understand the optimal treatment decisions for knee OA management. Purpose: To summarize the current published CPG recommendations for the role of injections in the nonoperative management of knee OA, specifically with the use of intra-articular hyaluronic acid (IA-HA), intra-articular corticosteroids (IA-CS), and platelet-rich plasma (PRP). Study Design: Systematic review. Methods: A comprehensive search identified all nonoperative knee OA CPGs within the ECRI (formerly Emergency Care Research Institute) Guidelines Trust database, the Guidelines International Network database, Google Scholar, and the Trip (formerly Turning Research Into Practice) database. Guideline recommendations were categorized into strong, conditional, or uncertain recommendations for or against the use of IA-HA, IA-CS, or PRP. Guideline recommendations were summarized and depicted graphically to identify trends in recommendations over time. Results: The search strategy identified 27 CPGs that provided recommendations. There were 20 recommendations in favor of IA-HA use, 21 recommendations in favor of IA-CS use, and 9 recommendations that were uncertain or unable to make a formal recommendation for or against PRP use based on current evidence. Most recommendations considered IA-HA and IA-CS use for symptom relief when other nonoperative options are ineffective. IA-CS were noted to provide fast and short-acting symptom relief for acute episodes of disease exacerbation, while IA-HA may demonstrate a relatively delayed but prolonged effect in comparison. The CPGs concluded that PRP recommendations currently lack evidence to definitively recommend for or against use. Conclusion: Available CPGs provide recommendations on injectables for knee OA treatment. General guidance from a global perspective concluded that IA-CS and IA-HA are favored for different needed responses and can be utilized within the knee OA treatment paradigm, while PRP currently has insufficient evidence to make a conclusive recommendation for or against its use.

orthopedics,sport sciences
Higher local recurrence rates after intralesional surgery for giant cell tumor of the proximal femur compared to other sites

C. Errani,S. Tsukamoto,G. Leone,M. Akahane,L. Cevolani,Piergiuseppe Tanzi,A. Kido,K. Honoki,Yasuhito Tanaka,D. Donati

DOI: https://doi.org/10.1007/s00590-017-1983-z

2017-06-06

European Journal of Orthopaedic Surgery & Traumatology

Abstract:
Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review.

Kaetlyn R. Arant,J. Katz,R. Loeser

DOI: https://doi.org/10.1001/jama.2020.22171

2021-02-09

Abstract:Importance Osteoarthritis (OA) is the most common joint disease, affecting an estimated more than 240 million people worldwide, including an estimated more than 32 million in the US. Osteoarthritis is the most frequent reason for activity limitation in adults. This Review focuses on hip and knee OA. Observations Osteoarthritis can involve almost any joint but typically affects the hands, knees, hips, and feet. It is characterized by pathologic changes in cartilage, bone, synovium, ligament, muscle, and periarticular fat, leading to joint dysfunction, pain, stiffness, functional limitation, and loss of valued activities, such as walking for exercise and dancing. Risk factors include age (33% of individuals older than 75 years have symptomatic and radiographic knee OA), female sex, obesity, genetics, and major joint injury. Persons with OA have more comorbidities and are more sedentary than those without OA. The reduced physical activity leads to a 20% higher age-adjusted mortality. Several physical examination findings are useful diagnostically, including bony enlargement in knee OA and pain elicited with internal hip rotation in hip OA. Radiographic indicators include marginal osteophytes and joint space narrowing. The cornerstones of OA management include exercises, weight loss if appropriate, and education-complemented by topical or oral nonsteroidal anti-inflammatory drugs (NSAIDs) in those without contraindications. Intra-articular steroid injections provide short-term pain relief and duloxetine has demonstrated efficacy. Opiates should be avoided. Clinical trials have shown promising results for compounds that arrest structural progression (eg, cathepsin K inhibitors, Wnt inhibitors, anabolic growth factors) or reduce OA pain (eg, nerve growth factor inhibitors). Persons with advanced symptoms and structural damage are candidates for total joint replacement. Racial and ethnic disparities persist in the use and outcomes of joint replacement. Conclusions and Relevance Hip and knee OA are highly prevalent and disabling. Education, exercise and weight loss are cornerstones of management, complemented by NSAIDs (for patients who are candidates), corticosteroid injections, and several adjunctive medications. For persons with advanced symptoms and structural damage, total joint replacement effectively relieves pain.

Medicine
EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis: 2023 update

Tuva Moseng,Theodora P M Vliet Vlieland,Simone Battista,David Beckwée,Vladimira Boyadzhieva,Philip G Conaghan,Daniela Costa,Michael Doherty,Andrew G Finney,Tsvetoslav Georgiev,Milena Gobbo,Norelee Kennedy,Ingvild Kjeken,Féline P B Kroon,L Stefan Lohmander,Hans Lund,Christian D Mallen,Karel Pavelka,Irene A Pitsillidou,Margaret P Rayman,Anne Therese Tveter,Johanna E Vriezekolk,Dieter Wiek,Gustavo Zanoli,Nina Østerås

DOI: https://doi.org/10.1136/ard-2023-225041

IF: 27.973

2024-01-11

Annals of the Rheumatic Diseases

Abstract:Introduction Hip and knee osteoarthritis (OA) are increasingly common with a significant impact on individuals and society. Non-pharmacological treatments are considered essential to reduce pain and improve function and quality of life. EULAR recommendations for the non-pharmacological core management of hip and knee OA were published in 2013. Given the large number of subsequent studies, an update is needed. Methods The Standardised Operating Procedures for EULAR recommendations were followed. A multidisciplinary Task Force with 25 members representing 14 European countries was established. The Task Force agreed on an updated search strategy of 11 research questions. The systematic literature review encompassed dates from 1 January 2012 to 27 May 2022. Retrieved evidence was discussed, updated recommendations were formulated, and research and educational agendas were developed. Results The revised recommendations include two overarching principles and eight evidence-based recommendations including (1) an individualised, multicomponent management plan; (2) information, education and self-management; (3) exercise with adequate tailoring of dosage and progression; (4) mode of exercise delivery; (5) maintenance of healthy weight and weight loss; (6) footwear, walking aids and assistive devices; (7) work-related advice and (8) behaviour change techniques to improve lifestyle. The mean level of agreement on the recommendations ranged between 9.2 and 9.8 (0–10 scale, 10=total agreement). The research agenda highlighted areas related to these interventions including adherence, uptake and impact on work. Conclusions The 2023 updated recommendations were formulated based on research evidence and expert opinion to guide the optimal management of hip and knee OA.

rheumatology
Strategies of osteoarthritis guidelines in clinical application

bin Wang,Dan Xing,Jianhao Lin

DOI: https://doi.org/10.3877/cma.j.issn.1674-134X.2017.01.021

2017-01-01

Abstract:Numerous guidelines have been developed aiming to optimize the diagnosis and treatment of osteoarthritis ( OA) .However , different evidences lead to different levels of recommendations , and many guidelines still present a lack of transparency which in some way limits its clinical use .In 2016, Osteoarthritis Research Society International ( OARSI) updated a previous guideline for OA management , developed a set of user-friendly management algorithms for common case scenarios ( hand OA, hip OA, knee OA), aiming to facilitate the translation of evidence-based recommendations into clinical practice .
Exercise in the management of osteoarthritis of the knee and hip

M A Minor

DOI: https://doi.org/10.1002/art.1790070407

Abstract:Osteoarthritis OA is a disorder that confines itself to affected joints; however, impairment, functional limitation, and disability related to OA can reach far beyond the perimeters of articular cartilage and subchondral bone. OA often is compared to other arthritides and defined by what it is not: OA is not a systemic disease; OA is not a disease of primary inflammation; OA is not life threatening. Too often OA also has been considered not interesting, not important, and not responsive to conservative treatment. However, reports documenting the personal and socioeconomic impact of OA are increasing recognition of its importance [1] and recent advances in understanding its pathogenesis are stimulating research [2]. OA is characterized by specific changes in articular cartilage and subchondral bone. Cartilage shows fibrillations, increased water content, and loss of integrity. Underlying bone is less compliant and may exhibit microfractures, sclerosis, and osteophytes at joint margins [3]. These changes result in increased friction, decreased shock absorption, and greater impact loading of the joint. The traditional view of OA is that the disease process starts with an unrepaired injury to articular cartilage. There is also evidence, however, that reduced compliance in bone and periarticular structures may initiate degenerative processes [4,5]. Although radiographic evidence of joint space narrowing and osteophytes may help confirm a diagnosis of OA, the clinical criteria for classification and reporting of hip and knee OA are described in terms of pain and limitation of motion [6,7] Table 1. Radiographic and laboratory data add little to the accuracy of these criteria [6]. Moreover, there is no clear association between radiographic findings and function or pain [8].(ABSTRACT TRUNCATED AT 250 WORDS)
Intra-Articular Steroid Injection for Patients with Hip Osteoarthritis: A Systematic Review and Meta-Analysis

Hui-Ming Zhong,Guang-Feng Zhao,Tiao Lin,Xin-Xin Zhang,Xin-Yu Li,Jun-Fan Lin,Si-Qi Zhao,Zhi-Jun Pan

DOI: https://doi.org/10.1155/2020/6320154

2020-01-01

BioMed Research International

Abstract:Purpose. The aim of this current review was to confirm the efficacy of intra-articular steroid therapy (IAST) for patients with hip osteoarthritis (OA) and discuss the duration and influential factors of IAST. Methods. Online databases (Medline, EMBASE, and Web of Science) were searched from inception to May 2019. Both randomized controlled trials (RCTs) and noncontrolled trials assessing the efficacy of hip IAST on pain were included. Common demographics data were extracted using a standardized form. Quality was assessed on the basis of Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence. Results. 12 trials met the inclusion criteria. According to data from individual trials, IAST had significant efficacy on hip OA in both immediate and delay pain reduction, which persisted up to 12 weeks after IAST. The influences of the baseline severity of hip OA or synovitis and injection dose or volume on the clinical outcome of IAST were still controversial. The IAST appeared to be well tolerant by most of the participants. Conclusion. IAST was proved to be an efficacious therapy in both immediate and delay pain reduction for hip OA patients within 12 weeks. The longer follow-up data of efficacy and safety and potentially influential factors are still unclear and needed further confirmation.
Limiting behavior of ac conductivity in ionically conducting crystals and glasses: A new universality.

W. Lee,J. F. Liu,A. Nowick

DOI: https://doi.org/10.1103/PHYSREVLETT.67.1559

IF: 8.6

1991-09-16

Physical Review Letters

Abstract:The ac conductivity \ensuremath{\sigma}(\ensuremath{\omega}) of three ionically conducting crystalline materials (${\mathrm{NaClZn}}^{2+}$, ${\mathrm{KTaO}}_{3}$:${\mathrm{Co}}^{3+}$,${\mathrm{H}}^{+}$, and ${\mathrm{CeO}}_{2}$:${\mathrm{Gd}}^{3+}$) and two glasses have been studied over an unusually wide temperature range. In all cases, limiting power-law behavior [exponent s=1 in \ensuremath{\sigma}(\ensuremath{\omega})=${\mathrm{\ensuremath{\sigma}}}_{0}$+A${\mathrm{\ensuremath{\omega}}}^{\mathit{s}}$] is observed at relatively low temperatures. It is concluded that this limiting behavior is a universal phenomenon. Available theoretical explanations have been examined and found to be unsatisfactory.
Structure, diversity, and evolution of protein toxins from spore-forming entomopathogenic bacteria.

R. D. de Maagd,A. Bravo,C. Berry,N. Crickmore,H. E. Schnepf

DOI: https://doi.org/10.1146/ANNUREV.GENET.37.110801.143042

2003-11-28

Annual Review of Genetics

Abstract:Gram-positive spore-forming entomopathogenic bacteria can utilize a large variety of protein toxins to help them invade, infect, and finally kill their hosts, through their action on the insect midgut. These toxins belong to a number of homology groups containing a diversity of protein structures and modes of action. In many cases, the toxins consist of unique folds or novel combinations of domains having known protein folds. Some of the toxins display a similar structure and mode of action to certain toxins of mammalian pathogens, suggesting a common evolutionary origin. Most of these toxins are produced in large amounts during sporulation and have the remarkable feature that they are localized in parasporal crystals. Localization of multiple toxin-encoding genes on plasmids together with mobilizable elements enables bacteria to shuffle their armory of toxins. Recombination between toxin genes and sequence divergence has resulted in a wide range of host specificities.
Non-operative management of shoulder osteoarthritis: Current concepts

Nobuyuki Yamamoto,Dominik Szymski,Andreas Voss,Hiroaki Ishikawa,Takayuki Muraki,Ronaldo A Cunha,Benno Ejnisman,Joseph Noack,Eric McCarty,Mary K Mulcahey,Eiji Itoi

DOI: https://doi.org/10.1016/j.jisako.2023.06.002

Abstract:Glenohumeral osteoarthritis (OA) is one of the most common causes of shoulder pain. Conservative treatment options include physical therapy, pharmacological therapy, and biological therapy. Patients with glenohumeral OA present shoulder pain and decreased shoulder range of motion (ROM). Abnormal scapular motion is also seen in patients as adaptation to the restricted glenohumeral motion. Physical therapy is performed to (1) decrease pain, (2) increase shoulder ROM, and (3) protect the glenohumeral joint. To decrease pain, it should be assessed whether the pain appears at rest or during shoulder motion. Physical therapy may be effective for motion pain rather than rest pain. To increase shoulder ROM, the soft tissues responsible for the ROM loss need to be identified and targeted for intervention. To protect the glenohumeral joint, rotator cuff strengthening exercises are recommended. Administration of pharmacological agents is the major part next to physical therapy in the conservative treatment. The main aim of pharmacological treatment is the reduction of pain and diminution of inflammation in the joint. To achieve this aim, non-steroidal anti-inflammatory drugs are recommended as first-line therapy. Additionally, the supplementation of oral vitamin C and vitamin D can help to slow down cartilage degeneration. Depending on the individual comorbidities and contraindications, sufficient medication with good pain reduction is thus possible for each patient. This interrupts the chronic inflammatory state in the joint and, in turn, enables pain-free physical therapy. Biologics such as platelet-rich plasma, bone marrow aspirate concentrate, and mesenchymal stem cells have gathered increased attention. Good clinical outcomes have been reported, but we need to be aware that these options are helpful in decreasing shoulder pain but neither stopping the progression nor improving OA. Further evidence of biologics needs to be obtained to determine their effectiveness. In athletes, a combined approach of activity modification and physical therapy can be effective. Oral medications can provide patients with transient pain relief. Intra-articular corticosteroid injection, which provides longer-term effects, must be used cautiously in athletes. There is mixed evidence for the efficacy of hyaluronic acid injections. There is still limited evidence regarding the use of biologics.
2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis

Karen B. Onel,Daniel B. Horton,Daniel J. Lovell,Susan Shenoi,Carlos A. Cuello,Sheila T. Angeles‐Han,Mara L. Becker,Randy Q. Cron,Brian M. Feldman,Polly J. Ferguson,Harry Gewanter,Jaime Guzman,Yukiko Kimura,Tzielan Lee,Katherine Murphy,Peter A. Nigrovic,Michael J. Ombrello,C. Egla Rabinovich,Melissa Tesher,Marinka Twilt,Marisa Klein‐Gitelman,Fatima Barbar‐Smiley,Ashley M. Cooper,Barbara Edelheit,Miriah Gillispie‐Taylor,Kimberly Hays,Melissa L. Mannion,Rosemary Peterson,Elaine Flanagan,Nadine Saad,Nancy Sullivan,Ann Marie Szymanski,Rebecca Trachtman,Marat Turgunbaev,Keila Veiga,Amy S. Turner,James T. Reston

DOI: https://doi.org/10.1002/acr.24853

2022-03-01

Abstract:OBJECTIVE: To provide updated guidelines for pharmacologic management of juvenile idiopathic arthritis (JIA), focusing on treatment of oligoarthritis, temporomandibular joint (TMJ) arthritis, and systemic JIA with and without macrophage activation syndrome. Recommendations regarding tapering and discontinuing treatment in inactive systemic JIA are also provided.METHODS: We developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation approach was used to rate the quality of evidence (high, moderate, low, or very low). A Voting Panel including clinicians and patients/caregivers achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations.RESULTS: Similar to those published in 2019, these JIA recommendations are based on clinical phenotypes of JIA, rather than a specific classification schema. This guideline provides recommendations for initial and subsequent treatment of JIA with oligoarthritis, TMJ arthritis, and systemic JIA as well as for tapering and discontinuing treatment in subjects with inactive systemic JIA. Other aspects of disease management, including factors that influence treatment choice and medication tapering, are discussed. Evidence for all recommendations was graded as low or very low in quality. For that reason, more than half of the recommendations are conditional.CONCLUSION: This clinical practice guideline complements the 2019 American College of Rheumatology JIA and uveitis guidelines, which addressed polyarthritis, sacroiliitis, enthesitis, and uveitis. It serves as a tool to support clinicians, patients, and caregivers in decision-making. The recommendations take into consideration the severity of both articular and nonarticular manifestations as well as patient quality of life. Although evidence is generally low quality and many recommendations are conditional, the inclusion of caregivers and patients in the decision-making process strengthens the relevance and applicability of the guideline. It is important to remember that these are recommendations. Clinical decisions, as always, should be made by the treating clinician and patient/caregiver.

rheumatology
Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines

Nigel K. Arden,Thomas A. Perry,Raveendhara R. Bannuru,Olivier Bruyère,Cyrus Cooper,Ida K. Haugen,Marc C. Hochberg,Timothy E. McAlindon,Ali Mobasheri,Jean-Yves Reginster

DOI: https://doi.org/10.1038/s41584-020-00523-9

IF: 32.286

2020-10-28

Nature Reviews Rheumatology

Abstract:Knee osteoarthritis (OA) is a heterogeneous disease associated with substantial effects on quality of life, and its clinical management is difficult. Among the several available guidelines for the management of knee OA, those from OARSI and ESCEO were updated in 2019. Here, we examine the similarities and differences between these two guidelines and provide a narrative to help guide health-care providers through the complexities of non-surgical management of knee OA. OARSI and ESCEO both recommend education, structured exercise and weight loss as core treatments, topical NSAIDs as first-line treatments and oral NSAIDs and intra-articular injections for persistent pain. Low-dose, short-term acetaminophen, pharmaceutical grade glucosamine and chondroitin sulfate are recommended by ESCEO whereas OARSI strongly recommends against their use (including all glucosamine and chondroitin formulations). Despite this difference, the two guidelines are consistent in the majority of their recommendations and provide useful treatment recommendations for individuals with OA and health-care providers.

rheumatology

Infant mortality and adult stature in Spain.

Computer Simulation of Vitamin D Transport

2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee

Tyrosine Phosphorylation of the Gα-Interacting Protein GIV Promotes Activation of Phosphoinositide 3-Kinase During Cell Migration

American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee

Surgical management of osteoarthritis of the knee: evidence-based clinical practice guideline methodological interpretation and recommendations explanation

Nonarthritic hip joint pain

Management of hip fractures in the elderly.

A critical appraisal of guidelines for the management of knee osteoarthritis using Appraisal of Guidelines Research and Evaluation criteria

A Systematic Review of Current Clinical Practice Guidelines on Intra-articular Hyaluronic Acid, Corticosteroid, and Platelet-Rich Plasma Injection for Knee Osteoarthritis: An International Perspective

Higher local recurrence rates after intralesional surgery for giant cell tumor of the proximal femur compared to other sites

Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review.

EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis: 2023 update

Strategies of osteoarthritis guidelines in clinical application

Exercise in the management of osteoarthritis of the knee and hip

Intra-Articular Steroid Injection for Patients with Hip Osteoarthritis: A Systematic Review and Meta-Analysis

Limiting behavior of ac conductivity in ionically conducting crystals and glasses: A new universality.

Structure, diversity, and evolution of protein toxins from spore-forming entomopathogenic bacteria.

Non-operative management of shoulder osteoarthritis: Current concepts

2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis

Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines